Premium
Cytokine Therapy After Bone Marrow Transplantation
Author(s) -
Dix Suzanne P.,
Gilmore Claire E.
Publication year - 1996
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1996.tb03641.x
Subject(s) - medicine , granulocyte macrophage colony stimulating factor , granulocyte colony stimulating factor , granulocyte , cytokine , bone marrow transplantation , bone marrow , toxicity , clinical trial , transplantation , immunology , intensive care medicine , chemotherapy
Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and granulocyte colony‐stimulating factor (G‐CSF) have an important yet controversial role in the care of patients undergoing bone marrow transplantation (BMT). Numerous studies have documented acceleration of neutrophil recovery by the agents. Because of the differences and lack of published clinical outcomes and of direct comparisons of the two CSFs, coupled with limited data from phase III trials, it is difficult to draw conclusions from the literature on the use of the agents after BMT. Issues that must be critically evaluated are toxicity profile, dose, initiation and duration of administration, route of administration, and cost.